Cargando…
The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
Cachexia, or wasting of skeletal muscle and fat, afflicts many patients with chronic diseases including cancer, organ failure, and AIDS. Muscle wasting reduces quality of life and decreases response to therapy. Cachexia is caused partly by elevated inflammatory cytokines, including interleukin-6 (IL...
Autores principales: | Au, Ernie D., Desai, Aditya P., Koniaris, Leonidas G., Zimmers, Teresa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241300/ https://www.ncbi.nlm.nih.gov/pubmed/28149280 http://dx.doi.org/10.3389/fphys.2016.00682 |
Ejemplares similares
-
STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2011) -
Differential Bone Loss in Mouse Models of Colon Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2017) -
Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia
por: Rupert, Joseph E., et al.
Publicado: (2021) -
Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia
por: Pedroso, Felipe E., et al.
Publicado: (2012) -
The impact of inflammation and acute phase activation in cancer cachexia
por: Robinson, Tyler P., et al.
Publicado: (2023)